| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 12/07/2005 | EP1326608B1 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers |
| 12/07/2005 | EP1317439B1 Acid-sensitive compounds, preparation and uses thereof |
| 12/07/2005 | EP1280558B1 Semi-solid delivery vehicle and pharmaceutical compositions |
| 12/07/2005 | EP1272059B1 Method of producing oily suspensions of water-soluble vitamins |
| 12/07/2005 | EP1267806B1 Use of cosmetic and pharmaceutical compositions comprising 2-decarboxy-2-phosphinico derivatives of prostaglandins |
| 12/07/2005 | EP1220887B1 Protein-containing granules and granule formulations |
| 12/07/2005 | EP1161241B1 Stable pharmaceutical application form for paroxetin anhydrate |
| 12/07/2005 | EP1156831B1 Hydroxyethy starch for the painless and tissue-conserving injection of medicaments |
| 12/07/2005 | EP1117412B1 Compositions containing diphosphonic acids |
| 12/07/2005 | EP1112060B1 Dosage form comprising liquid formulation |
| 12/07/2005 | EP1079809B1 Enteric coated pharmaceutical composition and method of manufacturing |
| 12/07/2005 | EP1056477B1 Nanoparticles comprising polyisobutylcyanoacrylate and cyclodextrins |
| 12/07/2005 | EP0988059B1 Human quinone reductase 2 conjugates for adept and gdept |
| 12/07/2005 | EP0794794B1 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| 12/07/2005 | EP0765163B1 Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| 12/07/2005 | EP0755269B1 Contrast agents |
| 12/07/2005 | EP0662002B1 Alginate-bioactive agent conjugates |
| 12/07/2005 | CN1705683A Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 12/07/2005 | CN1705682A Water-soluble iron-carbohydrate complexes, production thereof, and medicaments containing said complexes |
| 12/07/2005 | CN1705494A Colon cleansing compositions and methods |
| 12/07/2005 | CN1705472A Transdermal drug delivery system with improved water absorbability and adhesion properties |
| 12/07/2005 | CN1704122A Method for protecting viral vaccine and improving thermal stability utilizing heavy water |
| 12/07/2005 | CN1704121A Anti-angiogenic compositions and methods of use |
| 12/07/2005 | CN1704114A Synergistic antiplaque antigingivitis oral composition |
| 12/07/2005 | CN1230536C Tie-2 ligands, methods of making and uses thereof |
| 12/07/2005 | CN1230444C Use of HIV polypeptide or peptide or polynucleotide expression construct containing HIV-cell toxicant T-lymphocyte epitope |
| 12/07/2005 | CN1230441C Integrin binding peptide derivatives |
| 12/07/2005 | CN1230206C Polymer blends as biodegradable matrices for preparing biocomposites |
| 12/07/2005 | CN1230203C Muco-adhesive polymers, use thereof and method for producing the same |
| 12/07/2005 | CN1230202C External coated chewing gum products |
| 12/07/2005 | CN1230200C Stable enzymatic wound debrider |
| 12/07/2005 | CN1230197C Y-IFN liquid-droplet aerosol and method |
| 12/07/2005 | CN1230184C Prepns. for immunotherapy for cancer having bacterial somatic constituent as active ingredient |
| 12/07/2005 | CN1230179C Micronized eplerenone compositions |
| 12/07/2005 | CN1230167C Dual-release compositions of cyclooxygenase-2-inhibitor |
| 12/07/2005 | CN1230162C Pharmaceutical composition for modified release of an insulin sensitizing agent and another antidiabetic agent |
| 12/07/2005 | CN1230152C Hydrogel particle formulations |
| 12/07/2005 | CN1230150C Slow release pharmaceutical compositions comprising lithium carbonate |
| 12/07/2005 | CN1230141C Improved stability for injection solutions |
| 12/07/2005 | CA2509183A1 Topical anesthetic preparation for pretreatment for upper gastrointestinal endoscopy |
| 12/06/2005 | USRE38912 for treating a number of complaints, particularly respiratory diseases |
| 12/06/2005 | US6972322 Polypeptide for use in the treatment of cancerous, angiogenesis, inflammatory shock and autoimmune diseases |
| 12/06/2005 | US6972321 Monomeric protein of the TGF-β family |
| 12/06/2005 | US6972300 Compounds and compositions for delivering active agents |
| 12/06/2005 | US6972194 culturing cells in envelopes comprising acrylic amide homopolymers, for use in immunization against tumor cells and prophylaxis of diabetes; vaccines |
| 12/06/2005 | US6972193 dimerization or oligomerization of intracellular proteins to activate genetic transcription; signal transduction and activators of transcription |
| 12/06/2005 | US6972168 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 12/06/2005 | US6972130 mixtures of crystal structured hydroxyapatite, drugs and/or biological cells, having biocompatibility and bioresorption, for use in drug delivery |
| 12/06/2005 | US6972128 allogeneic immunotherapy; vaccines; immortalization |
| 12/06/2005 | US6972127 administering an effective dose of a polypeptide comprising an immunogenic fragment of A beta (SEQ ID NO:1) and an adjuvant in a regime effective to induce an immune response comprising antibodies to the A beta fragment; Alzheimer's disease |
| 12/06/2005 | CA2303177C Taste masked pharmaceutical compositions |
| 12/06/2005 | CA2079831C Biodegradable polymer composition |
| 12/02/2005 | CA2509077A1 Water-based compositions comprising a polyethylene glycol-based solubilizing agent and a taxane useful in the treatment of coronary artery disease |
| 12/01/2005 | WO2005113781A2 Vectors for use in gene and cancer therapy |
| 12/01/2005 | WO2005113608A1 Method of covalently linking hyaluronan and chitosan |
| 12/01/2005 | WO2005113605A1 Cross-linked antibodies |
| 12/01/2005 | WO2005113601A2 Antibodies and molecules derived therefrom that bind to steap-1 proteins |
| 12/01/2005 | WO2005113592A2 Interferon-alpha polypeptides and conjugates |
| 12/01/2005 | WO2005113012A2 Beta adrenergic drug conjugated to bone targeting moiety for modulating bone mass |
| 12/01/2005 | WO2005113011A2 Prodrugs of ion channel modulating compounds and uses thereof |
| 12/01/2005 | WO2005113010A1 Surface-modified and solubility-improved hard capsule |
| 12/01/2005 | WO2005113009A1 Solid pharmaceutical formulation |
| 12/01/2005 | WO2005113008A1 Delivery agents for enhancing mucosal absorption of therapeutic agents |
| 12/01/2005 | WO2005113007A2 Powders containing novel oligosaccharide mixtures and methods for producing the same |
| 12/01/2005 | WO2005113005A2 Transcutaneous and/or transdermal transport of materials |
| 12/01/2005 | WO2005113002A1 Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 12/01/2005 | WO2005112997A2 Composition and method for introduction of dna directed or direct rna interference sequence into targeted cells and tissues |
| 12/01/2005 | WO2005112996A1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 12/01/2005 | WO2005112984A2 Apparatus and method for transdermal delivery of parathyroid hormone agents |
| 12/01/2005 | WO2005112977A2 Compositions for treatment with glucagon-like peptide, and methods of making and using the same |
| 12/01/2005 | WO2005112974A2 Peptide-modified polyurethane compositions and associated methods |
| 12/01/2005 | WO2005112954A1 Nitric oxide releasing compositions and associated methods |
| 12/01/2005 | WO2005112934A1 Pharmaceutical compositions comprising zd6474 |
| 12/01/2005 | WO2005112909A1 Anti-inflammatory analgesic external aqueous liquid preparation |
| 12/01/2005 | WO2005112893A1 Microspheres comprising protein and showing injectability at high concentrations of said agent |
| 12/01/2005 | WO2005112889A2 Transmucosal delivery formulations |
| 12/01/2005 | WO2005112888A2 Methods for making injectable polymer hydrogels |
| 12/01/2005 | WO2005112887A2 Composition comprising intercalated functional-active organic compounds |
| 12/01/2005 | WO2005112886A2 Methods and articles for the delivery of therapeutic agents |
| 12/01/2005 | WO2005112883A1 Preserved pharmaceutical compositions comprising cyclodextrins |
| 12/01/2005 | WO2005112758A1 Contrast agents for magnetic resonance imaging |
| 12/01/2005 | WO2005112637A1 Formulations for non-parenteral use including hydrophobic cyclodextrins |
| 12/01/2005 | WO2005103081A3 Human monoclonal antibodies against cd20 |
| 12/01/2005 | WO2005092310A3 Chemically stable compositions of 4-hydroxy tamoxifen |
| 12/01/2005 | WO2005087951A3 Reagents, methods and kits for use in deactivating nucleic acids |
| 12/01/2005 | WO2005074888A3 Replacement enzyme cochleates |
| 12/01/2005 | WO2005061017A3 Electrically conductive adhesive hydrogels with solubilizer |
| 12/01/2005 | WO2005053650A8 Azithromycin dosage forms with reduced side effects |
| 12/01/2005 | WO2005049061A8 Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices |
| 12/01/2005 | WO2004037289A3 Novel injectable depot formulations |
| 12/01/2005 | US20050267293 Loading solution onto a hydrophobic interaction chromatography matrix equilibrated in aqueous buffer at a salt concentration high enough to promote matrix-protein interactions, applying a gradient of decreasing salt concentration, and collecting the conjugate, leaving the unconjugated albumin |
| 12/01/2005 | US20050267280 Lactone bearing absorbable polymers |
| 12/01/2005 | US20050267208 Nordihydroguaiartic derivatives for use in treatment of tumors |
| 12/01/2005 | US20050267201 Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| 12/01/2005 | US20050267190 Solid-state form of celecoxib having enhanced bioavailability |
| 12/01/2005 | US20050267169 Watersoluble prodrugs of propofol |
| 12/01/2005 | US20050267127 Guanidino phenylalanin compounds used as urokinase inhibitors |
| 12/01/2005 | US20050267125 High drug load tablet |
| 12/01/2005 | US20050267088 Compositions for treating hyperemia |
| 12/01/2005 | US20050267069 Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |